questionText: To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of Early Access Programmes on equity of access to (a) tofersen and (b) other innovative treatments.
answerText: Early access schemes for unlicenced medicines, where approval may be obtained in other markets, including where a licence exists but a National Institute for Health and Care Excellence decision is not available, are managed by companies to benefit patient...
heading: Medical Treatments and Tofersen